Discontinued — last reported Q3 '19
Corvex Stock options excluded as their inclusion would be anti-dilutive (in shares) increased by 8975.8% to $69.97M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12381.8%, from $560.60K to $69.97M.
A high number suggests that a significant portion of employee options are currently underwater.
The number of stock options or other equity instruments excluded from the diluted earnings per share calculation because...
Standard metric for all publicly traded companies with stock option plans.
other_antidilutive_securities_excluded_from_computation__8368cc| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q1 '25 | Q2 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $203.43K | $203.43K | $203.43K | $203.43K | $813.73K | $3.27M | $560.60K | $4.13M | $770.99K | $69.97M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +300.0% | +302.2% | -82.9% | +637.2% | -81.3% | >999% |
| YoY Change | — | — | — | — | +300.0% | >999% | -31.1% | +26.3% | — | >999% |